KRAS and metastatic colorectal cancer: Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR), either used alone, or a combination with cytotoxic agents have been demonstrated to prolong survival in patients with metastatic colorectal cancer (CRC) harboring KRAS wild-type or expanded RAS [1–6].